SI-BONE/$SIBN
1D1W1MYTD1Y5YMAX
Capital at risk
About SI-BONE
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
- Ticker
- $SIBN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 376
- Headquarters
- Santa Clara, United States
- Website
- si-bone.com
SI-BONE Metrics
BasicAdvanced
$835M
-
-$0.33
0.70
-
Price and volume
Market cap
$835M
Beta
0.7
52-week high
$21.89
52-week low
$11.48
Average daily volume
547K
Financial strength
Current ratio
9.147
Quick ratio
7.367
Long term debt to equity
23.235
Total debt to equity
23.469
Interest coverage (TTM)
-7.13%
Profitability
EBITDA (TTM)
-11.325
Gross margin (TTM)
79.53%
Net profit margin (TTM)
-6.85%
Operating margin (TTM)
-8.31%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
-4.62%
Return on equity (TTM)
-8.30%
Valuation
Price to revenue (TTM)
3.817
Price to book
4.54
Price to tangible book (TTM)
4.54
Price to free cash flow (TTM)
-185.858
Free cash flow yield (TTM)
-0.54%
Free cash flow per share (TTM)
-0.1
Growth
Revenue change (TTM)
15.30%
Earnings per share change (TTM)
-40.68%
3-year revenue growth (CAGR)
19.75%
3-year earnings per share growth (CAGR)
-37.13%
What the Analysts think about SI-BONE
Analyst ratings (Buy, Hold, Sell) for SI-BONE stock.
Analyst projections of the future price of SI-BONE stock.
Bulls say / Bears say
SI-BONE raised its 2026 revenue guidance to $231–233 million, implying 15–16% year-over-year growth. (Reuters)
SI-BONE’s Q2 FY26 net loss narrowed by 33.6% to $4.1 million, demonstrating improving profitability trends. (Reuters)
SI-BONE signed a distribution agreement with Smith+Nephew for its iFuse TORQ portfolio, expanding its global commercial footprint. (Reuters)
SI-BONE’s shares slid 10.29% after hours on Q2 earnings, signaling investor concerns over spending plans despite an earnings beat. (Reuters)
SI-BONE incurred Q2 operating expenses of $49.4 million, which may constrain margin expansion despite revenue growth. (Reuters)
Tenon Medical’s Catamaran SI Joint Fusion System received FDA clearance, posing competitive pressure on SI-BONE’s iFuse products. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
SI-BONE Financial Performance
Revenues and expenses
SI-BONE Earnings Performance
Company profitability
Upcoming events
No upcoming events
SI-BONE News
AllArticlesVideos
Funds containing SI-BONE
AllEURUSDGBP
Fund name | Fund size | $SIBN weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.